CA
VNDA icon

Calton & Associates’s Vanda Pharmaceuticals VNDA Stock Holding History

Calton & Associates’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,924
Closed -$145K – 393
2019
Q3 		$145K Buy
+10,924
New +$152K 0.03% 328

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Calton & Associates's VNDA Position: Q4 2019 in Review

Calton & Associates sold out of Vanda Pharmaceuticals (VNDA) in Q4 2019, closing a stake of 10,924 shares — an estimated $145K sold.

Calton & Associates first reported a position in VNDA in Q3 2019 and held it in 1 quarter. The position peaked at $145K in Q3 2019. 179 funds tracked by Wall St. Rank hold VNDA as of Q4 2019.

  • Calton & Associates reported no remaining Vanda Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Calton & Associates sold 10,924 Vanda Pharmaceuticals shares in Q4 2019, an estimated $145K.
  • Calton & Associates first reported a position in Vanda Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Calton & Associates's Vanda Pharmaceuticals position peaked at $145K in Q3 2019.
  • 179 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2019.

Based on Calton & Associates's 13F filing for Q4 2019, filed 3 Feb 2020.